Page 253 - Haematologica - Vol. 105 n. 6 - June 2020

Hypercoagulation and relapse in breast cancer
References
1. Falanga A, Schieppati F, Russo D. Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. Semin Thromb Hemost. 2015;41(7):756-764.
2. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clini- cal aspects. J Thromb Haemost. 2013;11(2):223-233.
3. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013;131 Suppl 1:S59-62.
4. Marchetti M, Diani E, ten Cate H, Falanga A. Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica. 2012;97(8):1173-1180.
5. Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res. 2009;148:31-41.
6. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49- 60.
7. Adams GN, Rosenfeldt L, Frederick M, et al. Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res. 2015;75(19):4235- 4243.
8. GuoR,YangJ,LiuX,WuJ,ChenY. Increased von Willebrand factor over decreased ADAMTS-13 activity is associat- ed with poor prognosis in patients with advanced non-small-cell lung cancer. J Clin Lab Anal. 2018;32(1).
9. Falanga A, Marchetti M, Massi D, et al. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600- mutated melanoma who are receiving BRAF inhibitors. J Am Acad Dermatol. 2016;74(6):1254-1256.e4.
10. Ma C, Lu B, Diao C, et al. Preoperative neu- trophil-lymphocyte ratio and fibrinogen level in patients distinguish between mus- cle-invasive bladder cancer and non-muscle- invasive bladder cancer. Onco Targets Ther. 2016;9:4917-4922.
11. Mandoj C, Pizzuti L, Sergi D, et al. Observational study of coagulation activa- tion in early breast cancer: development of a prognostic model based on data from the real world setting. J Transl Med. 2018;16(1):129.
12. Falanga A, Marchetti M. Hemostatic bio- markers in cancer progression. Thromb Res. 2018;164 Suppl 1:S54-S61.
13. Howlader N, Noone AM, Krapcho M et al. SEER cancer statistics review, 1975–2013. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2013/. 2016.
14. American cancer society. Breast Cancer Facts & Figures 2017-2018. Available at https://www.cancer.org/research/cancer- facts-statistics/breast-cancer-facts- figures.html.
15. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer sub- types. J Clin Oncol. 2010;28(20):3271-3277.
16. Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34(9):927-935.
17. Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care (Basel). 2017;12(2):102-107.
18. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA: NCCN; 2017. Ver. 3.2017. Available at: https://www.nccn.org/professionals/physi- cian_gls/pdf/breast.pdf. 2017.
19. Falanga A, Santoro A, Labianca R, et al. Hypercoagulation screening as an innova- tive tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thromb Res. 2016;140 Suppl 1:S55- 59.
20. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.
21. D'Alessio A, Marchetti M, Tartari CJ, et al. Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. Cancer Invest. 2017;35(7):490-499.
22. Marchetti M, Tartari CJ, Russo L, et al. Phospholipid-dependent procoagulant activ- ity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol. 2014;89(1):68-73.
23. Spiezia L, Campello E, Valle FD, Woodhams B, Simioni P. Factor VIIa-antithrombin com- plex: a possible new biomarker for activated coagulation. Clin Chem Lab Med. 2017;55(4):484-488.
24. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-3309.
25. Wen J, Yang Y, Ye F, et al. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of
breast cancer patients who underwent surgi-
cal treatment. Breast. 2015;24(6):745-750. 26. Krenn-Pilko S, Langsenlehner U, Stojakovic T, et al. An elevated preoperative plasma fib- rinogen level is associated with poor dis- ease-specific and overall survival in breast
cancer patients. Breast. 2015;24(5):667-672. 27. Liu YL, Lu Q, Liang JW, et al. High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive
breast cancer. Medicine. 2015;94(5):e481. 28. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and sur- vival in patients with metastatic breast can-
cer. Br J Cancer. 2002;86(3):389-395.
29. Rousseau A, Van Dreden P, Mbemba E, et al. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin genera- tion by apixaban, fondaparinux and enoxa-
parin. Thromb Res. 2015;136(6):1273-1279. 30. Rousseau A, Larsen AK, Van Dreden P, et al. Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells. Int J
Oncol. 2017;51(6):1747-1756.
31. Mego M, Zuo Z, Gao H, et al. Circulating
tumour cells are linked to plasma D-dimer levels in patients with metastatic breast can- cer. Thromb Haemost. 2015;113(3):593-598.
32. Pradhan S, Hassani I, Seeto WJ, Lipke EA. PEG-fibrinogen hydrogels for three-dimen- sional breast cancer cell culture. J Biomed Mater Res A. 2017;105(1):236-252.
33. Folsom AR, Delaney JA, Lutsey PL, et al. Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardio- vascular disease and all-cause mortality. Am J Hematol. 2009;84(6):349-353.
34. Miller GJ, Bauer KA, Howarth DJ, et al. Increased incidence of neoplasia of the digestive tract in men with persistent activa- tion of the coagulant pathway. J Thromb Haemost. 2004;2(12):2107-2114.
35. Silvestris N, Scartozzi M, Graziano G, et al. Basal and bevacizumab-based therapy- induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther. 2015;15(2):155-162.
36. Tinholt M, Viken MK, Dahm AE, et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer. 2014;14:845.
37. Fu S, Yun ZY, Cui MM, et al. Cancer antigen 15-3, platelet distribution width, and fibrino- gen in combination to distinguish breast cancer from benign breast disease in non- conclusive mammography patients. Oncotarget. 2017;8(40):67829-67836.
haematologica | 2020; 105(6)
1711